Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference GlobeNewswire - Tue Mar 11, 7:45AM CDT

AIM : 0.1180 (-1.67%)
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos ACCESS Newswire - Tue Mar 11, 3:45AM CDT

- Access video webcasts from all participating companies here

AIM : 0.1180 (-1.67%)
SONN : 1.3900 (unch)
MBRX : 1.0900 (-3.54%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week Stocktwits - Sun Mar 2, 10:04PM CST

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.5200 (-1.94%)
AIM : 0.1180 (-1.67%)
PEPG : 2.18 (-7.23%)
AEON : 0.7500 (+2.74%)
MBRX : 1.0900 (-3.54%)
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza GlobeNewswire - Fri Feb 28, 7:45AM CST

AIM : 0.1180 (-1.67%)
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance GlobeNewswire - Wed Feb 26, 12:20PM CST

AIM : 0.1180 (-1.67%)
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director GlobeNewswire - Wed Feb 26, 7:30AM CST

AIM : 0.1180 (-1.67%)
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer GlobeNewswire - Tue Feb 25, 7:30AM CST

AIM : 0.1180 (-1.67%)
AIM ImmunoTech Releases Virtual Investor “What This Means Segment” GlobeNewswire - Tue Feb 11, 7:45AM CST

AIM : 0.1180 (-1.67%)
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 GlobeNewswire - Tue Feb 11, 7:30AM CST

AIM : 0.1180 (-1.67%)
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks GlobeNewswire - Fri Feb 7, 7:50AM CST

AIM : 0.1180 (-1.67%)

Barchart Exclusives

Want Over 8% Yield? 1 ‘Strong Buy’ Stock to Consider Now. Barchart - Tue Mar 18, 6:30PM CDT
This stock has paid dividends since 1976 and has a “Strong Buy” consensus rating. Moreover, it offers a high yield of 8.11%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot